Prehabilitation During Neoadjuvant Chemoradiotherapy for Rectal Cancer
Launched by FUDAN UNIVERSITY · Aug 4, 2024
Trial Information
Current as of July 22, 2025
Completed
Keywords
ClinConnect Summary
This study is a prospective, single-center, randomized control trial. Including criteria were (1) Age between 18 and 80 years; (2) Histologically confirmed rectal adenocarcinoma；(3) Performance status (ECOG) 0-2; (4) Undergoing/scheduled for neoadjuvant chemoradiotherapy lasting at least 4 weeks. (5) Fried frailty score ≥2. Patients operated as emergency, pregnant or with comodities constraining physical exercise or causing disturbance of consciousness are excluded.
All particapants were recruited and randomly assigned to receive trimodel prehabilitation program or standard care. All patie...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with rectal cancer undergoing/scheduled for neoadjuvant chemoradiotherapy
- • Fried Frailty score≥2 (intermediately frail or frail)
- • Written consent informed
- Exclusion Criteria:
- • Co-morbiditie contraindicating physical exercise or causing disturbances of conciousness (dementia, Parkinson Disease, previous stroke with paresis, taking carbidopa/levodopa, donepezil or antidepressants)
- • Emergent surgery
- • ASA grade IV-V
- • Pregnancy (absence confirmed by serum/urine β-HCG) or breast-feeding
- • Known drug abuse/ alcohol abuse
About Fudan University
Fudan University, a prestigious comprehensive research university located in Shanghai, China, is committed to advancing medical science through innovative clinical research. Renowned for its rigorous academic standards and cutting-edge research facilities, Fudan University plays a pivotal role in the global health landscape by sponsoring a diverse array of clinical trials aimed at improving patient outcomes and addressing pressing medical challenges. Leveraging its multidisciplinary expertise and collaborative networks, the university strives to translate scientific discoveries into practical applications, fostering advancements in healthcare and contributing to the well-being of communities both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Trial Officials
Xu Jianmin, MD
Study Director
Fudan University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported